文献速递肝肾功能剂量调整特殊人群用药治疗药物监测与药物基因组学

极低体重老年患者按体重给予依诺肝素用于静脉血栓栓塞预防

Use of weight-based dosing of enoxaparin for venous thromboembolism prophylaxis in an extremely underweight elderly patient.
PubMed 文献 · Am J Health Syst Pharm · 2026-01-01

本病例报告描述一名68岁女性、体重仅21.8 kg的极低体重患者,因肺炎和慢阻肺急性加重入院,Padua评分5分、IMPROVE评分2分,需药物性VTE预防。临床采用按体重0.5 mg/kg(10 mg)皮下每日一次依诺肝素,并使用儿科稀释液给药,通过抗Xa峰值监测确认预防水平达标。

要点

  • 极低体重患者VTE预防缺乏循证剂量,本病例采用0.5 mg/kg依诺肝素每日一次。
  • 使用儿科稀释液实现低剂量精准给药,并以抗Xa峰值0.21 units/mL确认预防达标。
  • 体重<40 kg成人VTE预防的最佳抗凝剂量证据有限,需个体化并考虑监测。

核心结论

  • 本病例报道了极低体重老年患者使用按体重依诺肝素策略进行VTE预防,并达到治疗性预防抗Xa水平。

研究设计与样本

  • 单例病例报告:68岁女性,体重21.8 kg,因肺炎和慢阻肺急性加重入院。

主要发现

  • 患者Padua评分5分、IMPROVE评分2分,提示需要药物性VTE预防。
  • 依诺肝素0.5 mg/kg(10 mg)皮下每日一次,使用儿科稀释液给药。
  • 抗Xa峰值为0.21 units/mL,被认为达到合适的VTE预防水平。

关键数值与推荐

  • 依诺肝素剂量为0.5 mg/kg(10 mg)皮下每日一次。
  • 抗Xa峰值0.21 units/mL被视为合适的预防水平。
  • 文献回顾显示体重<40 kg成人VTE预防的最佳抗凝剂量证据很少。

临床怎么用

  • 对极低体重患者可考虑按体重计算依诺肝素预防剂量,并使用稀释液实现精准给药。
  • 可考虑监测抗Xa峰值以确认预防剂量是否达标。

局限性

  • 单例病例报告,不能推广至所有极低体重患者。
  • 文献缺乏体重<40 kg成人VTE预防的最佳抗凝剂量证据。
  • 尚无针对极端低体重患者达到治疗范围抗Xa水平的可用证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this report is to highlight a case of utilizing weight-based enoxaparin for prophylaxis of venous thromboembolism (VTE) in an elderly, extremely underweight patient. VTE represents a significant concern for hospitalized patients. There is a dearth of literature regarding utilization of low-molecular-weight heparins such as enoxaparin or unfractionated heparin in patients who are underweight. SUMMARY: In this case, a 68-year-old female who was extremely underweight (21.8 kg) presented to the emergency department in acute respiratory distress secondary to pneumonia and a chronic obstructive pulmonary disease exacerbation. The patient had a Padua score of 5 and an IMPROVE score of 2 that signified the necessity of pharmacologic VTE prophylaxis. A clinical decision was made to utilize a weight-based enoxaparin dosing strategy for VTE prophylaxis using a pediatric dilution to deliver the dose. Enoxaparin was initiated at 0.5 mg/kg (10 mg) subcutaneously daily and monitored via anti-factor Xa peak levels to verify that the dose provided an adequate prophylactic level. Ultimately, a dose of 0.5 mg/kg resulted in an appropriate anti-factor Xa level of 0.21 units/mL, equating to suitable VTE prophylaxis. CONCLUSION: A review of the literature revealed little evidence for optimal anticoagulation dosing for VTE prophylaxis in adult patients weighing under 40 kg. Various adjustment strategies have been utilized; however, there is no available evidence pertaining to patients at the extreme of low weight represented by the reported case or to attainment of an anti-factor Xa level within the therapeutic range in such patients. This case represents the use of a weight-based enoxaparin strategy for an extremely underweight elderly patient and the attainment of a therapeutic prophylactic anti-factor Xa level.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Lanier C, Lassiter M, Covert K, et al. Use of weight-based dosing of enoxaparin for venous thromboembolism prophylaxis in an extremely underweight elderly patient. Am J Health Syst Pharm. 2026. PMID: 41807259. doi:10.1093/ajhp/zxag080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。